Skip to content

Effects of Long-acting muscarinic antagonist(LAMA) and Long-acting beta-two-agonist (LABA) combination on dynamic pulmonary hyperinflation

Effects of Long-acting muscarinic antagonist(LAMA) and Long-acting beta-two-agonist (LABA) combination on dynamic pulmonary hyperinflation - Effect of bronchodilator combination on dynamic pulmonary hyperinflation

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000027521
Enrollment
38
Registered
2017-05-31
Start date
2017-04-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Treatment was on the day after completion of the baseline examination, and consisted of administration of tiotropium/olodaterol 5/5 micro grum inhalation solution (2.5/2.5 microgram per actuation) by

Sponsors

Shinshu University Hospital,Department of Rehabilitation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All patients suffered from smoking-related COPD without alpha 1 antitrypsin deficiency, and those with a smoking history of 10 pack-year or more including current smoker were selected for this study. In addition, as a substitute for LAMA and LABA during the washout period, patients who responded to symptoms with short-acting treatment were selected as eligible for inclusion. After receiving a thorough explanation of the study, patients who provided written consent were enrolled in the study

Exclusion criteria

Exclusion criteria: Patients with dysuria due to prostate hypertrophy, glaucoma, severe heart failure, exacerbation and/or respiratory infection within 3 months, prior history of lung surgery, severe heart disease, or impairment or difficulty in walking due to motor or cognitive dysfunction were excluded. Exacerbation history criteria was defined as an acute worsening of respiratory symptoms that result in additional therapy.

Design outcomes

Primary

MeasureTime frame
The primary outcome was defined as decrease in inspiratory capacity (IC) from rest by metronome-paced incremental hyperventilation(MPIH), which is an index of dynamic lung hyperinflation(DLH). after 8 weeks with treatment.

Secondary

MeasureTime frame
The secondary outcomes were COPD assessment test (CAT), FEV1, and 6-minute walking distance (6MWD). In addition to, as in previous studies, we investigated whether there are correlations between changes by treatment in DLH and exercise tolerance or dyspnea on exercise after 8weeks with treatment.

Countries

Japan

Contacts

Public ContactShohei Kawachi

Shinshu University Hospital Department of Rehabilitation

drodman@shinshu-u.ac.jp0263-37-2836

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026